Drugs that contain Elvitegravir

1. List of Vitekta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(3 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

VITEKTA family patents

11

United States

8

Norway

8

Japan

8

European Union

4

Argentina

3

Peru

2

Portugal

2

Malaysia

2

Russia

2

Spain

2

Brazil

2

New Zealand

2

Mexico

2

China

2

Taiwan, Province of China

2

Korea, Republic of

2

Hong Kong

2

South Africa

2

Canada

2

Cyprus

2

Slovenia

2

Australia

2

Denmark

1

Turkey

1

Germany

1

Croatia

1

Austria

1

Slovakia

1

Lithuania

1

Luxembourg

1

Hungary

1

Czech Republic

1

Israel

1

Poland

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in